Published in Biomed Res Int on August 28, 2014
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | NCT01829971
Micro-RNA Expression Profiles in High Risk Prostate Cancer | NCT01220427
Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets. Mol Cell Ther (2015) 1.32
Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis (2015) 0.97
Novel biomarkers for the detection of prostate cancer. J Clin Urol (2016) 0.77
Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression. Oncotarget (2016) 0.75
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 24.27
Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature (2010) 22.04
Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A (2009) 20.66
Landscape of transcription in human cells. Nature (2012) 20.18
RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science (2007) 18.59
Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell (2010) 17.87
Global identification of human transcribed sequences with genome tiling arrays. Science (2004) 17.85
Antisense transcription in the mammalian transcriptome. Science (2005) 15.69
The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res (2012) 15.41
Large-scale transcriptional activity in chromosomes 21 and 22. Science (2002) 14.01
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 13.82
Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes. Cell (2011) 10.56
Natural RNA circles function as efficient microRNA sponges. Nature (2013) 8.93
Circular RNAs are a large class of animal RNAs with regulatory potency. Nature (2013) 8.54
Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature (2008) 7.64
Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell (2010) 6.94
Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol Cell (2010) 6.88
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85
Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. Mol Cell (2011) 6.83
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun (2011) 5.95
lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3' UTRs via Alu elements. Nature (2011) 5.42
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res (1999) 4.67
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer (2010) 4.53
miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay. Science (2012) 4.44
starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res (2013) 4.33
Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell (2013) 4.28
Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet (2009) 3.94
lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature (2013) 3.77
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature (2012) 3.08
The expanding RNA polymerase III transcriptome. Trends Genet (2007) 3.07
Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer (2011) 3.02
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther (2009) 2.92
Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol (2013) 2.84
Active Wnt proteins are secreted on exosomes. Nat Cell Biol (2012) 2.81
GW182 proteins directly recruit cytoplasmic deadenylase complexes to miRNA targets. Mol Cell (2011) 2.80
Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer (2009) 2.76
Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer (2012) 2.74
Long noncoding RNAs are rarely translated in two human cell lines. Genome Res (2012) 2.64
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med (2011) 2.62
Transcriptome-wide miR-155 binding map reveals widespread noncanonical microRNA targeting. Mol Cell (2012) 2.54
MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther (2008) 2.43
RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res (2012) 2.41
The genomic binding sites of a noncoding RNA. Proc Natl Acad Sci U S A (2011) 2.34
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med (2013) 2.28
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol (2012) 2.24
PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci U S A (2000) 2.17
PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology (2007) 2.14
Deep sequencing of human nuclear and cytoplasmic small RNAs reveals an unexpectedly complex subcellular distribution of miRNAs and tRNA 3' trailers. PLoS One (2010) 2.12
Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet (2013) 2.11
Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci (2010) 2.03
Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene (2004) 2.02
Secretory COPII coat component Sec23a is essential for craniofacial chondrocyte maturation. Nat Genet (2006) 1.92
Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol (2006) 1.90
Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res (2010) 1.89
Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell (2011) 1.86
Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol (2011) 1.85
Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate (2010) 1.81
The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res (2010) 1.75
Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology (2011) 1.73
MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene (2012) 1.73
Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol (2013) 1.64
A novel role of myosin VI in human prostate cancer. Am J Pathol (2006) 1.59
The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One (2008) 1.56
Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res (2012) 1.55
Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J (2013) 1.48
MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer (2011) 1.47
MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate (2010) 1.44
Mouse miRNA-709 directly regulates miRNA-15a/16-1 biogenesis at the posttranscriptional level in the nucleus: evidence for a microRNA hierarchy system. Cell Res (2011) 1.44
The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol (2009) 1.42
GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. Prostate (2008) 1.42
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res (2014) 1.39
Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget (2014) 1.38
The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol Oncol (2012) 1.33
MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One (2012) 1.30
Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochim Biophys Acta (2012) 1.25
Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer (2013) 1.25
miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene (2013) 1.24
Most of the human genome is transcribed. Genome Res (2001) 1.18
A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate (2012) 1.18
Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells. PLoS Genet (2013) 1.18
Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma. Mol Cancer Res (2011) 1.17
The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget (2014) 1.14
Large oncosomes mediate intercellular transfer of functional microRNA. Cell Cycle (2013) 1.12
A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate (2010) 1.11
miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells. Cancer Res (2014) 1.08
Dynamic recruitment of microRNAs to their mRNA targets in the regenerating liver. BMC Genomics (2013) 1.06
The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Mol Cancer Res (2014) 1.03
miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene (2013) 1.02
Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing. Mol Cancer Res (2013) 1.02
Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer. PLoS One (2013) 1.01
miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS One (2013) 1.00
Association between lncrna PCGEM1 polymorphisms and prostate cancer risk. Prostate Cancer Prostatic Dis (2013) 1.00
miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res (2012) 1.00